Clinical Trial Details

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (TBI) Protocol NO: Neu-2566-TBI-001
Study Purpose
The purpose of this study is primarily to assess the safety of the new investigational drug, NNZ-2566, in human subjects with TBI. . An additional purpose of the study is to find out if NNZ-2566 improves abnormal brain electrical activity and reduces or prevents brain seizures in the acute stage of TBI.
Study Plan
Intravenous Infusion of the study drug or Placebo: . Neither you nor the study doctors will know which experimental medication you received until the study is completed.

Principal Investigator
Andrew J. Kerwin, M.D., FACS

Sub Investigator
J. Bracken Burns, D.O., M.S.

Sub Investigator
Jin H. Ra, M.D.

Sub Investigator
Joseph J. Tepas III, M.D.

News & Announcements

Against the Odds


Tim Callahan laid awkwardly on the ground, wishing he could yell for help and seriously unsure whether his head was still attached to h... [full story]

Several faculty recognized for longstanding service at UFCOMJ


Joseph Tepas III, MD, a professor of surgery and pediatrics, has worn many hats during his lengthy career at the University of Florida... [full story]

Patients experience “a whole new world” after weight loss surgery


Imagine waiting in line for hours to take your kids on a theme park ride, only to be kicked off because you’re too heavy. Imagin... [full story]

Upcoming Events

There are currently no events to display. Check back soon!